Sevoflurane and Percutaneous Coronary Intervention by Stent

• Status: Terminated
• Trial end date: 2020-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality.

Patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, MB isoform (CK - MB), on the order of 30% of all angioplasty.

Possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of CK - MB values in excess of 100% baseline.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Dante Pazzanese de Cardiologia
• Treatments: Sevoflurane

Criteria

Inclusion Criteria:

1. Both gender.

2. Patients with coronary artery disease candidates for coronary angioplasty stent.

3. Cardiac catheterization on an urgent basis.

4. Coronary angioplasty in elective and urgency.

5. Age less than 80 years.

Exclusion Criteria:

1. Patients aged greater than or equal of 80 years.

2. Angioplasty balloon catheter statement.

3. Myocardial infarction with ST-segment elevation.

4. Angioplasty in saphenous vein grafts in patients after surgical revascularization.

5. Patient pregnant.

6. Dialytic insufficiency renal.

7. Patients submited a urgent cardiac catheterization but not progress with coronary angioplasty stent.